These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 29548318)

  • 61. Comparison of Costs and Clinical Outcomes Between Hospital and Outpatient Administration of Omalizumab in Patients With Severe Uncontrolled Asthma.
    Chiner E; Fernández-Fabrellas E; Landete P; Novella L; Ramón M; Sancho-Chust JN; Senent C; Berraondo J
    Arch Bronconeumol; 2016 Apr; 52(4):211-6. PubMed ID: 26651624
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying doses of inhaled corticosteroids in adolescents and adults with asthma: a systematic review and network meta-analysis.
    Oba Y; Anwer S; Maduke T; Patel T; Dias S
    Cochrane Database Syst Rev; 2022 Dec; 12(12):CD013799. PubMed ID: 36472162
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy.
    Dal Negro RW; Tognella S; Pradelli L
    J Asthma; 2012 Oct; 49(8):843-8. PubMed ID: 22954018
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effectiveness and pharmacoeconomic analysis of the treatment of severe asthma with omalizumab in clinical practice.
    Martínez-Moragón E; Climent M; Chiner E; Fernández-Aracil C; Sánchez-Toril F; Lluch-Tortajada I
    Farm Hosp; 2019 May; 43(3):101-109. PubMed ID: 31072288
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry.
    Gibson PG; Reddel H; McDonald VM; Marks G; Jenkins C; Gillman A; Upham J; Sutherland M; Rimmer J; Thien F; Katsoulotos GP; Cook M; Yang I; Katelaris C; Bowler S; Langton D; Robinson P; Wright C; Yozghatlian V; Burgess S; Sivakumaran P; Jaffe A; Bowden J; Wark PA; Yan KY; Kritikos V; Peters M; Hew M; Aminazad A; Bint M; Guo M
    Intern Med J; 2016 Sep; 46(9):1054-62. PubMed ID: 27350385
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Preliminary clinical observation of omalizumab therapy for moderate to severe asthma].
    Wu PH; Dong C; Xie JX; Zhang XX; Liu J; Ouyang M; Ma JJ; Huang WH; Ou CX; Li J; Zhang QL
    Zhonghua Jie He He Hu Xi Za Zhi; 2021 Jul; 44(7):611-618. PubMed ID: 34256447
    [No Abstract]   [Full Text] [Related]  

  • 67. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
    Liu MC; Chipps B; Munoz X; Devouassoux G; Bergna M; Smith SG; Price RG; Galkin DV; Azmi J; Mouneimne D; Albers FC; Chapman KR
    Respir Res; 2021 May; 22(1):144. PubMed ID: 33971856
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Concomitant asthma medications in moderate-to-severe allergic asthma treated with omalizumab.
    Chen H; Eisner MD; Haselkorn T; Trzaskoma B
    Respir Med; 2013 Jan; 107(1):60-7. PubMed ID: 23083840
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Trends in Omalizumab Utilization for Asthma: Evidence of Suboptimal Patient Selection.
    Jeffery MM; Shah ND; Karaca-Mandic P; Ross JS; Rank MA
    J Allergy Clin Immunol Pract; 2018; 6(5):1568-1577.e4. PubMed ID: 28958746
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Outcomes before and after treatment escalation to Global Initiative for Asthma steps 4 and 5 in severe asthma.
    Sullivan PW; Campbell JD; Ghushchyan VH; Globe G
    Ann Allergy Asthma Immunol; 2015 Jun; 114(6):462-9. PubMed ID: 25890451
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Impact of omalizumab in children from a middle-income country with severe therapy-resistant asthma: A real-life study.
    Pitrez PM; de Souza RG; Roncada C; Heinzmann-Filho JP; Santos G; Pinto LA; Jones MH; Stein RT
    Pediatr Pulmonol; 2017 Nov; 52(11):1408-1413. PubMed ID: 29027379
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Assessment of long-term omalizumab treatment in patients with severe allergic asthma long-term omalizumab treatment in severe asthma.
    Özgür ES; Özge C; Ïlvan A; Naycı SA
    J Asthma; 2013 Aug; 50(6):687-94. PubMed ID: 23557459
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Addition of leukotriene receptor antagonists to inhaled corticosteroids improved QOL of patients with bronchial asthma surveyed in suburban Tokyo, Japan.
    Ohshima N; Matsui H; Matsui Y; Kawashima M; Shimada M; Higaki N; Shoji S; Wada H; Fujita A; Watanabe H; Yamaguchi N; Matsuoka R; Oki K; Takahashi H; Suzuki M; Yamazaki H; Yoshizawa M; Goto H
    Allergol Int; 2011 Dec; 60(4):473-81. PubMed ID: 21681017
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Healthcare costs and resources utilization in children with difficult-to-control asthma treated with biologic therapies: A population-based cohort study.
    Monzio Compagnoni M; Conflitti C; Capuano V; Bonaiti G; Franchi M; Vimercati C; Biondi A; Luppi F; Corrao G; Faverio P
    Pediatr Pulmonol; 2024 Feb; 59(2):408-416. PubMed ID: 37991180
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma.
    Crossingham I; Turner S; Ramakrishnan S; Fries A; Gowell M; Yasmin F; Richardson R; Webb P; O'Boyle E; Hinks TS
    Cochrane Database Syst Rev; 2021 May; 5(5):CD013518. PubMed ID: 33945639
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Real-world Clinical Characteristics, Treatment Patterns, and Exacerbations in US Patients With Asthma Newly Treated With Omalizumab.
    Ke X; Kavati A; Wertz D; Huang Q; Wang L; Willey VJ; Stephenson JJ; Ortiz B; Panettieri RA; Corren J
    Clin Ther; 2018 Jul; 40(7):1140-1158.e4. PubMed ID: 30049502
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Quality of life in patients with allergic asthma on treatment with omalizumab].
    Aguilar-Hinojosa NK; Sánchez-Tec G
    Rev Alerg Mex; 2018; 65(4):349-356. PubMed ID: 30602204
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy.
    Odajima H; Ebisawa M; Nagakura T; Fujisawa T; Akasawa A; Ito K; Doi S; Yamaguchi K; Katsunuma T; Kurihara K; Kondo N; Sugai K; Nambu M; Hoshioka A; Yoshihara S; Sato N; Seko N; Nishima S
    Allergol Int; 2015 Oct; 64(4):364-70. PubMed ID: 26433533
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Resource utilization in asthma: combined fluticasone propionate/salmeterol compared with inhaled corticosteroids.
    Friedman HS; Yawn BP
    Curr Med Res Opin; 2007 Feb; 23(2):427-34. PubMed ID: 17288696
    [TBL] [Abstract][Full Text] [Related]  

  • 80. "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study.
    Brusselle G; Michils A; Louis R; Dupont L; Van de Maele B; Delobbe A; Pilette C; Lee CS; Gurdain S; Vancayzeele S; Lecomte P; Hermans C; MacDonald K; Song M; Abraham I
    Respir Med; 2009 Nov; 103(11):1633-42. PubMed ID: 19619998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.